Press Releases

Amplicon premieres products on world's largest nicotine forum

Amplicon will premiere two products at the Global Forum on Nicotine, which will be held in Warsaw on 16-18 June 2022. The world's largest annual conference in the tobacco and nicotine industry attracts a large number of visitors with experts, media, consumers, and industry professionals from many countries.

In Warsaw, Amplicon will present two dry white nicotine pouches with newly developed profiles for how flavor and nicotine are released. The technology is based on Amplicon's IP, based on ceramic biomaterials, and is a completely new generation of nicotine products with unique properties for a better user experience.

The theme of this year's conference, 'Tobacco Harm Reduction - here for good', is fully in line with the products that Amplicon is developing within the Amp01 project.

"We have conducted tests with very good results and we look forward to receiving the international response at the forum," says Tomas Hammargren, Chairman of Amplicon.

GFN22 explores the science of safer products and addresses the changes in policies and regulations needed to maximize their potential. Although most of the restrictions on COVID-19 have been removed in many countries, the conference will also be broadcast live, via the FGN platform.

GFN is the only international conference that focuses on the important role that safer nicotine products have in helping people quit smoking. Safer nicotine products include e-cigarettes (so-called vapes), nicotine pouches, oral tobacco, such as Swedish snus, and heated tobacco products. https://gfn.events

Torbjörn W. Larsson
CEO
Phone: +46 (0)70 747 65 99
Email: torbjorn.walkerlarsson@emplicure.com

Erik Magnusson
CFO, Investor Relations
Phone: +46 (0)708 565 245
Email: erik.magnusson@emplicure.com

Tomas Hammargren
Chairman, Amplicon AB
Phone: +46 (0) 706 494 549
Email: tomas.hammargren@amplic.se

Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons above, on April 25, 2022 at 13:00 CET.

Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with white nicotine pouches as the first product. Read more at www.emplicure.com

2022-06-22
Regulatory

Amplicon, a wholly owned subsidiary of Emplicure AB that focuses on developing consumer products, successfully showcased two dry white nicotine-pouch products at the Global Forum on Nicotine in Warsaw on 16-18 June 2022.

2022-06-16
Regulatory

Emplicure's CEO Torbjörn Walker Larsson presented the company at Aktiespararnas Småbolagsdagar in Stockholm yesterday. If you could not participate or missed the event, click on the link below to watch the presentation in streaming mode.

2022-06-15
Regulatory

Amplicon, a wholly owned subsidiary of Emplicure AB (publ), that focuses on developing consumer products, today announced that it has filed at the European Union Intellectual Property Office (EUIPO) for a trademark registration for its leading product.

2022-05-17
Regulatory

Emplicure AB (publ) ("Emplicure" or the "Company") announces the outcome of the exercise of warrants of series TO1, which were issued during the second quarter of 2021. A total of 5,902,512 warrants of series TO1 were exercised, corresponding to approximately 61.5 percent of outstanding warrants of series TO1, for subscription of 5,902,512 shares at a subscription price of SEK 2.09 per share. Through the exercise of the warrants of series TO1, Emplicure receives approximately SEK 12.3 million before issue costs.

2022-05-11
Regulatory

Johan Wieslander, who is a board member of Emplicure AB (publ) ("Emplicure" or the "Company"), has acquired an additional 1,500,000 warrants of series TO1, in addition to the warrants previously held by him that have already been exercised for subscription of shares in the Company. Johan Wieslander  has exercised the the additional 1,500,000 warrants for subscription of 1,500,000 shares in the Company, meaning that the Company receives approximately SEK 3.1 million.

2022-05-11
Regulatory

Today, May 11 2022, is the last day for trading with warrants of series TO1 in Emplicure AB (publ) ("Emplicure" or the "Company"). The subscription period runs up to and including May 13 2022. Each warrant of series TO1 entitles the holder to subscribe for one (1) new share in the Company at a price of SEK 2.09 per share.

2022-05-05
Regulatory

Members of the board of directors and management team of Emplicure AB (publ) ("Emplicure" or the "Company") intend to exercise held warrants of series TO1 and enter into a lock-up undertaking comprising all securities held by such persons at the time of the undertaking as well as the shares obtained through exercise of the warrants of series TO1. The number of warrants of series TO1 that the board of directors and the management team intend to exercise amounts to 588,227 warrants, corresponding to 6.1 percent of outstanding warrants of series TO1, corresponding to a subscription of 588,277 new shares to a value of approximately SEK 1.2 million. The lock-up commitments comprise 31.5 percent of the shares in the Company, calculated based on the number of shares in the Company at the time of this press release, and the commitments run up to and including 31 December 2022. The lock-up commitments also include the subscribed shares in connection with the exercise of warrants of series TO1. If all the warrants of series TO1 are exercised, the lock-up commitments will comprise 23.4 percent of the shares in the Company.

2022-04-29
Regulatory

Today, April 29 2022, the subscription period for warrants of series TO1 in Emplicure AB (publ) ("Emplicure" or "the Company") begins. The subscription period runs up to and including 13 May 2022. Each warrant of series TO1 entitles the holder to subscribe for one (1) new share in the Company at a price of SEK 2.09 per share. In order for the warrants not to expire without value, it is required that the holder actively subscribes for shares no later than 13 May 2022, or alternatively sells the warrants no later than 11 May 2022.

2022-04-28
Regulatory

During the second quarter of 2021, Emplicure AB (publ) ("Emplicure" or "the Company") issued 9,600,000 warrants of series TO1. Each warrant entitles the holder to subscribe for one (1) new share in the Company. According to the board of directors' resolution, which was resolved pursuant to the authorization by the annual general meeting held on 13 April 2021, the subscription price for the warrants of series TO1 shall be set at 70 percent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during the measurement period from and including 12 April 2022 up to and including 27 April 2022, provided however that the subscription price may not be determined to an amount less than the quota value for the Company's shares and not be determined to an amount exceeding SEK 6.23 per share. The volume-weighted average price of the Company's share during the measurement period amounted to approximately SEK 2.98 and the subscription price has thus been set at SEK 2.09. Subscription of shares with through the exercise of warrants of series TO1 shall be made during the period from and including 29 April 2022 up to and including 13 May 2022.

2022-04-26

Under årets första kvartal har vi tagit viktiga steg i arbetet med att vidareutveckla och optimera formuleringarna i våra två huvudprojekt, Empli03 och Amp01, där vi följer den plan vi presenterade i samband med börsintroduktionen.

1
2
3
4
5
6

GET STARTED

Do you want to know more?

Contact us today.